HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Clinical trials for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising new combo therapy offers hope for lymphoma patients who Can't have transplants
Disease control Recruiting nowThis study is for people with a type of blood cancer (large B-cell lymphoma) that has come back or not gotten better after earlier treatments, and who cannot have a stem cell transplant. The trial tests whether adding either tazemetostat or zanubrutinib to a standard two-drug com…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
New drug cocktail aims to tame aggressive lymphoma
Disease control Recruiting nowThis early-stage trial tests whether adding the targeted drug polatuzumab vedotin (with or without another drug, glofitamab) to standard chemotherapy is safe and tolerable for people with untreated, fast-growing B-cell lymphomas. About 56 participants will receive the combination…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug targets tough lymphoma in early trial
Disease control Recruiting nowThis study tests a new drug called pidnarulex (CX-5461) in 50 people with aggressive B-cell lymphomas that have MYC gene changes. The goal is to find a safe dose and see if it can shrink tumors. Participants have already tried other treatments and have limited options.
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for aggressive lymphoma: targeted therapy before chemo shows promise
Disease control Recruiting nowThis study tests a two-step treatment for people with a fast-growing type of lymphoma that is hard to treat. First, a targeted drug (loncastuximab tesirine) plus rituximab is given to attack cancer cells directly. Then, standard chemotherapy (DA-EPOCH-R) is used to kill remaining…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New drug cocktail shows promise for tough lymphoma
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. About 18 adults with untreated or minimally treated disease will receive the combination. The goal is to improve c…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
New combo therapy offers hope for Hard-to-Treat leukemia
Disease control Recruiting nowThis study combines a targeted antibody-drug (inotuzumab ozogamicin) with low-intensity chemotherapy to treat acute lymphoblastic leukemia (ALL). It includes older adults (60+) with newly diagnosed ALL and younger adults (18-59) who are not fit for standard chemo, as well as pati…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:13 UTC